Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,186.00
Bid: 12,186.00
Ask: 12,188.00
Change: 16.00 (0.13%)
Spread: 2.00 (0.016%)
Open: 12,114.00
High: 12,258.00
Low: 12,114.00
Prev. Close: 12,170.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Promising Start Amid Blue-Chip Exec Changes

Fri, 22nd Nov 2019 08:52

(Alliance News) - Stocks in London were broadly higher early Friday, after China said it wants a trade deal with US, though it did not shy away from fighting talk, and Land Securities and Rightmove both announced key executive changes.

The FTSE 100 index of London large-cap stocks was 59.31 points higher, or 0.8%, at 7,297.86 on Friday morning. The mid-cap FTSE 250 was 15.20 points up, or 0.1%, at 20,385.06, but the AIM All-Share was 0.2% higher at 904.07.

The Cboe UK 100 index was 1.0% higher at 12,383.68. The Cboe UK 250 was 0.5% up early on Friday at 18,354.37, but the Cboe UK Small Companies was marginally lower at 11,272.21.

Property developer Land Securities was 0.6% higher after it said Mark Allan will join as chief executive after leaving his role as CEO of St Modwen Properties in May next year. Allan was formerly was the CEO of student accommodation provider Unite Group between 2006 and 2016, Landsec noted.

He is to join the FTSE 100 firm "no later than June 1, 2020", Landsec added.

St Modwen, down 1.5%, making it one of the worst FTSE 250 performers, said it was "disappointed" to lose Allan but has begun the process to replace him.

Also making a key executive change was real estate firm Rightmove, up 1.0% in early dealings, naming Andrew Fisher as non-executive chair with effect on January 1. He is currently a non-executive director at retailer Marks & Spencer and insurance comparison site Moneysupermarket.com, and was formerly executive chair at music recognition mobile app Shazam.

FTSE 250 gambling software firm Playtech was down 1.8% early on Friday after it warned adjusted earnings before interest, tax, depreciation and amortisation will be "a little below consensus" in 2019.

The company, which provides betting terminals for the likes of Labrokes and Paddy Power, said: "Following a positive start to the second half, trading conditions in TradeTech have been highly challenging during September and October."

However, Playtech said trading in its Core B2B Gambling and Snaitech arms "continues to exceed management expectations, while trading in Asia has remained stable". Revenue in Regulated B2B Gambling was up 12% on a year before in the four months from July to October.

Also issuing a full-year earnings warning was Coats Group, down 11% and languishing at the foot of the FTSE 250 index.

On the back of a "slower sales performance", the industrial threads maker is now guiding for adjusted operating profit between USD196 million and USD201 million.

Adjusted operating profit in 2018 came in at USD195 million.

Elsewhere on the London Main Market, investment manager Brooks Macdonald said it will part with up to GBP39 million in cash to acquire Edinburgh-based Cornelian Asset Managers.

Brooks said: "The total net consideration is expected to be up to GBP39 million, with initial consideration being GBP31 million, of which GBP22 million will be paid in cash and GBP9m in Brooks Macdonald shares."

Brooks will launch a share placing to raise GBP30 million. The firm will price its shares at 1,775 pence apiece. The stock was down 1.9% at 1,790.0 pence each.

Pharma giant AstraZeneca edged 1.0% higher following Thursday's late news that its drug Calquence had been approved in the US for adults patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma.

The approval by the US Food & Drug Administration results from positive analyses from two phase 3 clinical trials, Elevate-TN in patients with previously untreated CLL and Ascend in patients with relapsed or refractory CLL.

In European equities, the CAC 40 index in Paris was up 0.6% and the DAX 30 in Frankfurt also 0.6% higher.

Stocks in the US ended in the red on Thursday. The S&P 500, the Dow Jones Industrial Average and Nasdaq Composite all closed 0.2% lower.

Stocks in Asia were mixed on Friday, the Nikkei 225 closed 0.3% higher in Tokyo, with Hong Kong's Hang Seng 0.5% higher in late trade. The Shanghai Composite closed 0.6% lower in China.

"Global markets remained focused on US-China trade negotiations, taking a modicum of comfort on reports that Chinese VP Liu has invited US Trade Rep Lighthizer to Beijing for further talks," Lloyds bank research said.

On Friday, President Xi Jinping said China wanted to hammer out a deal but was "not afraid" to fight back when necessary. He told former US officials and other foreign dignitaries at a meeting in Beijing that he wanted to "work for a phase-one agreement on the basis of mutual respect and equality".

The remarks came two days after Donald Trump complained Beijing had not made sufficient concessions so far, making him reluctant to conclude a bargain.

Mining stocks in London received a slight uptick following the latest trade war developments.

Antofagasta topped the blue-chip index, rising 2.5% early on Friday. Glencore was just behind, 2.4% higher, with BHP and Rio Tinto both up 1.7%.

A slew of flash PMI readings will provide some distraction from the trade tit-for-tat, with manufacturing and services numbers from Japan, Germany, the eurozone, the UK and the US.

In Japan, the Jibun Bank flash composite PMI registered a slight rise in November but pointed to a "strongly possibility" the country's economy will contract in the fourth quarter.

The flash composite purchasing manager's index read 49.9 in November, up from October's actual figure of 49.1. The flash manufacturing PMI showed a slight rise to 48.6 in November from 48.4 the previous month, while the flash services PMI indicated a rise into expansionary territory, increasing to 50.4 from 49.7.

In Germany, the flash composite PMI was 49.2 in November, up from 48.9 in October. The manufacturing PMI improved, but services slipped a bit.

The eurozone reading is due at 0900 GMT, before the UK reading at 0930 GMT.

"We look for a small decline in the November manufacturing PMI to 49.0, but a rise in the services PMI to 50.5. These numbers remain consistent with flat or slightly negative quarterly growth," Lloyds said, ahead of the UK print.

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.